Literature DB >> 33919314

A Potential SARS-CoV-2 Variant of Interest (VOI) Harboring Mutation E484K in the Spike Protein Was Identified within Lineage B.1.1.33 Circulating in Brazil.

Paola Cristina Resende1,2, Tiago Gräf1,3, Anna Carolina Dias Paixão1,2, Luciana Appolinario1,2, Renata Serrano Lopes1,2, Ana Carolina da Fonseca Mendonça1,2, Alice Sampaio Barreto da Rocha1,2, Fernando Couto Motta1,2, Lidio Gonçalves Lima Neto4, Ricardo Khouri1,3,5, Camila I de Oliveira1,3,5, Pedro Santos-Muccillo1,3,6, João Felipe Bezerra7, Dalane Loudal Florentino Teixeira8, Irina Riediger9, Maria do Carmo Debur9, Rodrigo Ribeiro-Rodrigues10,11, Anderson Brandao Leite12, Cliomar Alves do Santos13, Tatiana Schäffer Gregianini14, Sandra Bianchini Fernandes15, André Felipe Leal Bernardes16, Andrea Cony Cavalcanti17, Fábio Miyajima1,18, Claudio Sachhi19, Tirza Mattos20, Cristiano Fernandes da Costa21, Edson Delatorre1,22, Gabriel L Wallau1,23, Felipe G Naveca1,24, Gonzalo Bello1,25, Marilda Mendonça Siqueira1,2.   

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Brazil was dominated by two lineages designated as B.1.1.28 and B.1.1.33. The two SARS-CoV-2 variants harboring mutations at the receptor-binding domain of the Spike (S) protein, designated as lineages P.1 and P.2, evolved from lineage B.1.1.28 and are rapidly spreading in Brazil. Lineage P.1 is considered a Variant of Concern (VOC) because of the presence of multiple mutations in the S protein (including K417T, E484K, N501Y), while lineage P.2 only harbors mutation S:E484K and is considered a Variant of Interest (VOI). On the other hand, epidemiologically relevant B.1.1.33 deriving lineages have not been described so far. Here we report the identification of a new SARS-CoV-2 VOI within lineage B.1.1.33 that also harbors mutation S:E484K and was detected in Brazil between November 2020 and February 2021. This VOI displayed four non-synonymous lineage-defining mutations (NSP3:A1711V, NSP6:F36L, S:E484K, and NS7b:E33A) and was designated as lineage N.9. The VOI N.9 probably emerged in August 2020 and has spread across different Brazilian states from the Southeast, South, North, and Northeast regions.

Entities:  

Keywords:  Brazil; E484K; SARS-CoV-2; genomic epidemiology; variant of Interest

Year:  2021        PMID: 33919314     DOI: 10.3390/v13050724

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  14 in total

1.  Phylogenetic analysis and comparative genomics of SARS-CoV-2 from survivor and non-survivor COVID-19 patients in Cordoba, Argentina.

Authors:  Nadia B Olivero; Ana S Gonzalez-Reiche; Viviana E Re; Gonzalo M Castro; María B Pisano; Paola Sicilia; María G Barbas; Zenab Khan; Adriana van de Guchte; Jayeeta Dutta; Paulo R Cortes; Mirelys Hernandez-Morfa; Victoria E Zappia; Lucia Ortiz; Ginger Geiger; Daniela Rajao; Daniel R Perez; Harm van Bakel; Jose Echenique
Journal:  BMC Genomics       Date:  2022-07-14       Impact factor: 4.547

2.  Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico.

Authors:  Abril Paulina Rodríguez-Maldonado; Joel Armando Vázquez-Pérez; Alberto Cedro-Tanda; Blanca Taboada; Celia Boukadida; Claudia Wong-Arámbula; Tatiana Ernestina Nuñez-García; Natividad Cruz-Ortiz; Gisela Barrera-Badillo; Lucía Hernández-Rivas; Irma López-Martínez; Alfredo Mendoza-Vargas; Juan Pablo Reyes-Grajeda; Nicolas Alcaraz; Fernando Peñaloza-Figueroa; Dulibeth Gonzalez-Barrera; Daniel Rangel-DeLeon; Luis Alonso Herrera-Montalvo; Fidencio Mejía-Nepomuceno; Alejandra Hernández-Terán; Mario Mújica-Sánchez; Eduardo Becerril-Vargas; José Arturo Martínez-Orozco; Rogelio Pérez-Padilla; Jorge Salas-Hernández; Alejandro Sanchez-Flores; Pavel Isa; Margarita Matías-Florentino; Santiago Ávila-Ríos; José Esteban Muñoz-Medina; Concepción Grajales-Muñiz; Angel Gustavo Salas-Lais; Andrea Santos Coy-Arechavaleta; Alfredo Hidalgo-Miranda; Carlos F Arias; José Ernesto Ramírez-González
Journal:  Arch Virol       Date:  2021-08-27       Impact factor: 2.574

3.  Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance.

Authors:  Hannah Wang; Jacob A Miller; Michelle Verghese; Mamdouh Sibai; Daniel Solis; Kenji O Mfuh; Becky Jiang; Naomi Iwai; Marilyn Mar; ChunHong Huang; Fumiko Yamamoto; Malaya K Sahoo; James Zehnder; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2021-07-19       Impact factor: 5.948

4.  Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19.

Authors:  Tanuj Sharma; Mohammad Hassan Baig; Mohd Imran Khan; Saqer S Alotaibi; Mohammed Alorabi; Jae-June Dong
Journal:  Saudi Pharm J       Date:  2022-01-19       Impact factor: 4.562

5.  Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.

Authors:  Diego A Álvarez-Díaz; Katherine Laiton-Donato; Orlando Alfredo Torres-García; Hector Alejandro Ruiz-Moreno; Carlos Franco-Muñoz; Maria Angie Beltran; Marcela Mercado-Reyes; Miguel Germán Rueda; Ana Luisa Muñoz
Journal:  Virus Res       Date:  2021-11-12       Impact factor: 3.303

6.  First and second COVID-19 waves in Brazil: A cross-sectional study of patients' characteristics related to hospitalization and in-hospital mortality.

Authors:  Felipe André Zeiser; Bruna Donida; Cristiano André da Costa; Gabriel de Oliveira Ramos; Juliana Nichterwitz Scherer; Nêmora Tregnago Barcellos; Ana Paula Alegretti; Maria Letícia Rodrigues Ikeda; Ana Paula Wernz C Müller; Henrique C Bohn; Ismael Santos; Luiza Boni; Rodolfo Stoffel Antunes; Rodrigo da Rosa Righi; Sandro José Rigo
Journal:  Lancet Reg Health Am       Date:  2021-11-01

Review 7.  Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: Impact on Disease Severity.

Authors:  Andrea De Lorenzo; Vanessa Estato; Hugo C Castro-Faria-Neto; Eduardo Tibirica
Journal:  J Inflamm Res       Date:  2021-05-27

8.  Epidemic Spread of SARS-CoV-2 Lineage B.1.1.7 in Brazil.

Authors:  Filipe R R Moreira; Diego M Bonfim; Danielle A G Zauli; Joice P Silva; Aline B Lima; Frederico S V Malta; Alessandro C S Ferreira; Victor C Pardini; Wagner C S Magalhães; Daniel C Queiroz; Rafael M Souza; Victor E V Geddes; Walyson C Costa; Rennan G Moreira; Nuno R Faria; Carolina M Voloch; Renan P Souza; Renato S Aguiar
Journal:  Viruses       Date:  2021-05-26       Impact factor: 5.048

9.  A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.

Authors:  Federico Bertoglio; Viola Fühner; Maximilian Ruschig; Philip Alexander Heine; Leila Abassi; Thomas Klünemann; Ulfert Rand; Doris Meier; Nora Langreder; Stephan Steinke; Rico Ballmann; Kai-Thomas Schneider; Kristian Daniel Ralph Roth; Philipp Kuhn; Peggy Riese; Dorina Schäckermann; Janin Korn; Allan Koch; M Zeeshan Chaudhry; Kathrin Eschke; Yeonsu Kim; Susanne Zock-Emmenthal; Marlies Becker; Margitta Scholz; Gustavo Marçal Schmidt Garcia Moreira; Esther Veronika Wenzel; Giulio Russo; Hendrikus S P Garritsen; Sebastian Casu; Andreas Gerstner; Günter Roth; Julia Adler; Jakob Trimpert; Andreas Hermann; Thomas Schirrmann; Stefan Dübel; André Frenzel; Joop Van den Heuvel; Luka Čičin-Šain; Maren Schubert; Michael Hust
Journal:  Cell Rep       Date:  2021-07-07       Impact factor: 9.995

10.  Clinical characteristics and outcomes of COVID-19 patients admitted to the intensive care unit during the first year of the pandemic in Brazil: a single center retrospective cohort study.

Authors:  Thiago Domingos Corrêa; Thais Dias Midega; Karina Tavares Timenetsky; Ricardo Luiz Cordioli; Carmen Silvia Valente Barbas; Moacyr Silva Júnior; Bruno de Arruda Bravim; Bruno Caldin Silva; Gustavo Faissol Janot de Matos; Ricardo Kenji Nawa; Fabrício Rodrigues Torres de Carvalho; Verônica Neves Fialho Queiroz; Roberto Rabello Filho; Felipe Maia de Toledo Piza; Adriano José Pereira; Marcele Liliane Pesavento; Raquel Afonso Caserta Eid; Bento Fortunato Cardoso Dos Santos; Andreia Pardini; Vanessa Damázio Teich; Claudia Regina Laselva; Miguel Cendoroglo Neto; Sidney Klajner; Leonardo José Rolim Ferraz
Journal:  Einstein (Sao Paulo)       Date:  2021-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.